reports
Beyond Air® Secures Up to $32 Million to Accelerate Growth
Beyond Air® Secures Up to $32 Million to Accelerate Growth Enters agreements for a $12 million promissory note and a $20 million equity line of credit with Streeterville Capital Proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025, including $12 million from the promissory note Extends cash runway into calendar 2027 GARDEN CITY, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the p...
Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conf...
Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its second fiscal quarter ended September 30, 2025 on Monday, November 10, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm E...
First Merchants Corporation Announces Third Quarter 2025 Earnings per ...
First Merchants Corporation Announces Third Quarter 2025 Earnings per Share MUNCIE, Ind., Oct. 22, 2025 (GLOBE NEWSWIRE) -- First Merchants Corporation (NASDAQ - FRME) (the "Corporation") Third Quarter 2025 Highlights: Net income available to common stockholders was $56.3 million and diluted earnings per common share totaled $0.98 in the third quarter of 2025, compared to $48.7 million and $0.84 in the third quarter of 2024, and $56.4 million and $0.98 in the second quarter of 2025.Robust capital position with Common Equity Tier 1 Capital Ratio of 11.34% and Tangible Common Equity to Ta...
Verrica Pharmaceuticals Receives Positive Feedback from the European M...
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union – EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH® in the EU and that no additional Phase 3 studies are required – – Verrica is initiating activities to support this regulatory submission, which could be filed as early as Q4 2026 – WEST CHESTER, Pa...
First Merchants Corporation Announces Cash Dividend on Its Preferred S...
First Merchants Corporation Announces Cash Dividend on Its Preferred Stock MUNCIE, Ind., Oct. 15, 2025 (GLOBE NEWSWIRE) -- First Merchants Corporation (NASDAQ: FRME) has declared a quarterly cash dividend of $46.88 per share on its 7.50% Non-Cumulative Perpetual Preferred Stock Series A, represented by depositary shares (NASDAQ: FRMEP) each representing a 1/100th interest in a share of the Series A preferred stock. Holders of depositary shares will receive $0.4688 per depositary share. The dividend will be payable on November 14, 2025, to stockholders of record on October 31, 2025. About...
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2...
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will be presenting both an oral presentation and a poster on VP-315, its oncolytic peptide for the treatment of basal cell carcinoma (BCC), at the Society for Immu...
First Merchants Corporation to Report Third Quarter 2025 Financial Res...
First Merchants Corporation to Report Third Quarter 2025 Financial Results, Host Conference Call and Webcast MUNCIE, Ind., Oct. 02, 2025 (GLOBE NEWSWIRE) -- First Merchants Corporation (Nasdaq: FRME) will release its third quarter 2025 financial results on Wednesday, October 22, 2025. The Corporation will host an earnings conference call and webcast at 9:00 a.m. (ET) on Thursday, October 23, 2025. To access via phone, participants will need to register using the following link where they will be provided a phone number and access code: () In order to view the webcast and presentation sl...
First Merchants Corporation and First Savings Financial Group, Inc. An...
First Merchants Corporation and First Savings Financial Group, Inc. Announce Signing of Definitive Merger Agreement MUNCIE, Ind. and JEFFERSONVILLE, Ind., Sept. 25, 2025 (GLOBE NEWSWIRE) -- First Merchants Corporation (Nasdaq: FRME) (“First Merchants”) and First Savings Financial Group, Inc., (Nasdaq: FSFG) (“First Savings”) today announced they have entered into a definitive merger agreement pursuant to which First Savings will merge with and into First Merchants in an all-stock transaction currently valued at approximately $241.3 million. Immediately following the merger, First Savings ...
Verrica Pharmaceuticals Announces That Development Partner, Torii Phar...
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum – Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need of patients with molluscum – – Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics co...
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Mos...
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational therapy, BA-101, for the treatment of Glioblastoma (GBM). GBM is an aggressive primary brain tumor with limited tre...
- Jonathan Moreland
PRGO PERRIGO CO. PLC
POST POST HOLDINGS INC.
LKQ LKQ CORPORATION
ICUI ICU MEDICAL INC.
HBNC HORIZON BANCORP INC
EMN EASTMAN CHEMICAL COMPANY
D DOMINION ENERGY INC
CPRX CATALYST PHARMACEUTICALS
COTY COTY INC. CLASS A
ASYS AMTECH SYSTEMS INC.
AROW ARROW FINANCIAL CORP.
RLMD RELMADA THERAPEUTICS
QRHC QUEST RESOURCE HOLDING
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
NTLA INTELLIA THERAPEUTICS INC.
MX MAGNACHIP SEMICONDUCTOR CORP.
NWPP NEW PEOPLES BANKSHARES INC.
BHR BRAEMAR HOTELS & RESORTS
CCEL CRYO-CELL INTERNATIONAL
REZI RESIDEO TECHNOLOGIES
WU INC.
AVTR THE WESTERN UNION COMPANY
SELF AVANTOR
PGEN INC.
COO SELF STORAGE GROUP
REYN INC.
STTK PRECIGEN INC
ENOV THE COOPER COMPANIES INC.
BLIN REYNOLDS CONSUMER PRODUCTS INC.
EBC SHATTUCK LABS
NRGV ENOVIS CORPORATION
ONL BRIDGELINE DIGITAL INC
OBIO EASTERN BANKSHARES INC
ET ENERGY VAULT HOLDINGS INC
PROP ORION OFFICE REIT INC
BKKT ORCHESTRA BIOMED HOLDINGS INC
ISPO ENERGY TRANSFER LP
AFCG PRAIRIE OPERATING CO.
FG BAKKT HOLDINGS INC.
NIQ INSPIRATO INCORPORATED
STSS AFC GAMMA
FEAM INC.
SINT F AND G ANNUITIES AND LIFE
VWFB INC.
NIQ GLOBAL INTELLIGENCE PLC
SHARPS TECHNOLOGY INC.
5E ADVANCED MATERIALS INC.
SINTX TECHNOLOGIES INC.
VWF BANCORP
INC.
- Jonathan Moreland
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global In...
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference GARDEN CITY, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY. An on-demand webc...
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Ann...
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference WEST CHESTER, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. H.C. Wainwright 27th Annual Global Investment Confer...
Beyond Air Signs New International LungFit PH® Distribution Agreements...
Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion people GARDEN CITY, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patient lives, today announced the expansion of its global LungFit® PH distribution network. The Company has recentl...
First Merchants Corporation Announces Cash Dividend
First Merchants Corporation Announces Cash Dividend MUNCIE, Ind., Aug. 15, 2025 (GLOBE NEWSWIRE) -- First Merchants Corporation declared a cash dividend on August 15, 2025 of $0.36 per common share. The dividend is payable on September 19, 2025, to common shareholders of record as of September 5, 2025. About First Merchants Corporation: First Merchants Corporation is a financial holding company headquartered in Muncie, Indiana. The Corporation has one full-service bank charter, First Merchants Bank. The Bank also operates as First Merchants Private Wealth Advisors (as a division of Firs...
Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Pr...
Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update Increased revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024 Awarded a national group purchasing agreement for therapeutic gases by Premier, Inc., which has more than 4,350 member hospitals and health systems in its network Reaffirm revenue guidance of $12-$16 million for the full fiscal year 2026 Conference call at 4:30 p.m. ET today, August 12th GARDEN CITY, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAI...
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results – Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in milestone revenue from Torii Pharmaceutical – – Completed Successful End of Phase 2 Meeting for VP-315 for Basal Cell Carcinoma; Company is preparing for the Phase 3 program and exploring non-dilutive opportunities for financing further development – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., Aug. ...
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Result...
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025 WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, August 12, 2025, to discuss the Company's financial results for the second quarter ending June 30, 2025, and provide a corporate update. In...
- Jonathan Moreland
ANTM ANTHEM INC.
SSB SOUTH STATE CORPORATION
SNV SYNOVUS FINANCIAL CORP.
SIGI SELECTIVE INSURANCE GROUP INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
RLI RLI CORP.
PSX PHILLIPS 66
PRGS PROGRESS SOFTWARE CORPORATION
PNFP PINNACLE FINANCIAL PARTNERS INC.
NVCR NOVOCURE LTD.
MTH MERITAGE HOMES CORPORATION
MSCI MSCI INC. CLASS A
MOFG MIDWESTONE FINANCIAL GROUP
FBIZ FIRST BUSINESS FINANCIAL SERVICES
CNC CENTENE CORPORATION
CHTR CHARTER COMMUNICATIONS INC. CLASS A
ALGN ALIGN TECHNOLOGY INC.
UPS UNITED PARCEL SERVICE INC. CLASS B
PETS PETMED EXPRESS INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
PBT PERMIAN BASIN ROYALTY TRUST
LIND LINDBLAD EXPEDITIONS HOLDINGS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
PLBC PLUMAS BANCORP
CZWI CITIZENS COMMUNITY BANCORP
MBIN MERCHANTS BANCORP
PGC PEAPACK-GLADSTONE FINANCIAL CORP.
LOOP LOOP INDUSTRIES
CHMG CHEMUNG FINANCIAL CORP.
FVCB FVCBANKCORP
TLRY TILRAY
TROX TRONOX HOLDINGS PLC
AMTB AMERANT BANCORP (A)
PCB PACIFIC CITY FINANCIAL CORP
DMAC DIAMEDICA THERAPEUTICS INC.
CRDF CARDIFF ONCOLOGY INC
ABSI ABSCI CORP
NSPR INSPIREMD INC
BRCC BRC INC
JMSB JOHN MARSHALL BANCORP INC
PRME PRIME MEDICINE INC
MMC MARSH & MCLENNAN COMPANIES INC.
STRW STRAWBERRY FIELDS REIT INC.
AURX NUO THERAPEUTICS
DMA INC.
MRAI DESTRA MULTI ALTERNATIVE FUND
GF MARPAI
CVM INC.
THE NEW GERMANY FUND
INC.
CEL-SCI CORPORATION
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.